Anterior ischemic optic neuropathy and activated protein C resistance: A case report and review of the literature

Journal of Neuro-Ophthalmology

Volumn 17, Issue 3, 1997, Pages 162-165

  Worrall, Bradford B ^a   Moazami, Golnaz ^a   Odel, Jeffery G ^a   Behrens, Myles M ^a  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

Activated protein c resistance; Anterior ischemic optic neuropathy; Thrombophilia

Indexed keywords

EID: 84975485312     PISSN: 10708022     EISSN: 15365166     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Arnold AC, Hepler RS. Natural history of Non-arteritic anterior ischemic optic neuropathy. J Neuroophthalmol 1994; 2: 66-9.
2. Beri M, Klugman MR, Kohler JA, Hayreh SS. Anterior ischemic optic neuropathy VII: incidence of bilaterality and various influencing factors. Ophthalmology 1987; 94: 1020-128.
3. Borchert M, Lessell S. Progressive and recurrent non-arteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1988; 106: 443-9.
4. Feit RH, Tomsak RL, Ellenberger C. Structural factors in pathogenesis of ischemic optic neuropathy. Am J Ophthalmol 1989; 98: 105-8.
5. Tice DA. Ischemic optic neuropathy and cardiac disease. Ann Thome Surg 1987; 44: 677.
6. Sweeny PJ, Breuer AC, Selhorst JB, et al. Ischemic optic neuritis: a complication of cardiopulmonary bypass surgery. Neurology 1982; 32: 560-2.
7. Ellenberger C Jr. Ischemic optic neuropathy as possible early complication of vascular hypertension. Am J Ophthalmol 1979; 88: 1045-51.
8. Hayreh SS. Anterior ischemic neuropathy: clinical features and pathogenesis of post-hemorrhagic amaurosis. Ophthalmology 1987; 94: 1488-502.
9. Hayreh SS, Joos KM, Podhajsky PA, Long CR. Systemic diseases associated with non-arteritic AION. Am J Ophthalmol 1994; 118: 766-80.
10. Acheson JF, Sanders MD. Coagulation abnormalities in ischemic optic neuropathy. Eye 1994; 8(pt. 1): 89-92.
11. Bokarewa MI, Bremme K, Falk G, Sten-Linder M, Egberg N, Blombeck M. Studies on phospholipid antibodies, APC-resistance and associated mutation in the coagulation factor V gene. Thromb Res 1995; 78: 193-200.
12. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
13. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl. J Med 1984; 330: 517-22.
14. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
15. Zoller B, Dahlback B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343(8912): 1536-8.
16. Bauer KA. Hypercoagulability: a new cofactor In the protein C anticoagulant pathway. N Engl J Med 1994; 330: 566-7.
17. Schafer AI. Hypercoagulable states: molecular genetics to clinical practice. Lancet 1994; 344(8939-8940): 1739-12.
18. Dahlback B. Molecular genetics of thrombophilia: factor V gene mutation causing resistance to activated protein C as a basis of the hypercoagulable state. J Lab Clin Med 1995; 125: 566-71.
19. Rosendaal FR, Koster T, Vendenbroucke JP, Reitman PH. High risk of thrombosis in patients homozygous for factor V Leiden. Blood 1995; 85: 1504-8.
20. Dahlback B. Resistance to activated protein C, the Arg506 to Gin mutation in factor V gene, and venous thrombosis. Thromb Hae-most 1995; 73: 739-12.
21. Rosen S, Johansson K, Lindberg B, Dahlback B. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. Thromb Hacmost 1994; 72: 255-60.
22. de Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-6.
23. Press RD, Goodnight SH. Predisposition to thrombosis by a factor V mutation causing hereditary resistance to activated protein C. West J Med 1995; 162: 450-2.
24. Legnani C, Palareti G, Biagi R, Coccheri S. Activated protein C resistance in deep-venous thrombosis. Lancet 1994; 343(8896): 541-2.
25. Vandenbroucke JP, Koster T, Briet E, Reitsman PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutations [letter]. Lancet 1994; 344(8935): 1435-7.
26. Cook G, Walker ID, McCall F, Conkie JA, Greer IA. Familial thrombophilia and activated protein C resistance: thrombotic risk in pregnancy? Br J Hematol 1994; 87: 873-5.
27. Lindblad B, Svensson PJ, Dahlback B. Arterial and venous thromboembolism with fatal outcome and resistance to activated protein C [letter]. Lancet 1994; 343(8902): 917.
28. Ma DD, Aboud MR, Williams BG, Isbister JP. Activated protein C resistance and inherited factor V mis-sense mutation in patients with venous and arterial thrombosis in a hematology clinic. Aust N ZJ Med 1995; 25: 151-4.
29. Emmerich J, Poirier O, Evans A, et al. Myocardial infarction, Arg 506 to Gin factor V mutation, and activated protein C resistance [letter]. Lancet 1995; 345(8945): 321.
30. Holm J, Zoller B, Svensson PJ, Berntorp E, Erhart L, Dahlback B. Myocardial infarction associated with homozygous resistance to activated protein C [letter]. Lancet 1994; 344(8927): 952-3.
31. Halmayer WM, Hausofer A, Schon R, Fischer M. The prevalence of poor anticoagulant response to activated protein C among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinolysis 1994; 5: 51-7.
32. Forsyth PD, Dolan G. Activated protein C resistance in cases of cerebral infarction fletter]. Lancet 1995; 345(8952): 795.
33. Simioni P, de Ronde H, Prandoni P, Saladini M, Berlina RM, Girolami A. Ischemic stroke in young patients with activated protein C resistance: a report of three cases belonging to different kindred. Stroke 1995; 26: 885-890.
34. Albuchner JF, Guiraud-Chaumeil B, Chollet F, Cadroy Y. Sie P. Frequency of resistance to activated protein C due to factor V mutation in young patients with ischemic stroke [letter]. Stroke 1996; 27: 766-7.
35. Marz W, Seydewitz H, Winklemann B, Chen M, Nauck M, Witt I. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease [letter]. Lancet 1995; 345(8948): 526.
36. Samani NJ, Lodwick D, Martin D, Kimber P. Resistance to activated protein C and risk of premature myocardial infarction [letter]. Lancet 1994; 344(8938): 1709-10.
37. Simioni P, Girolami A. Homozygous factor V-deficient patients show resistance to activated protein C whereas heterozygotes do not. Blood Coagul Fibrinolysis 1994; 5: 825-7.
38. Zoller B, Bernsdotter A, Garcia de Frutos P, Dahlback B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-23.
39. Bokarewa MI, Blomback M, Egberg N, Rosen S. A new variant of interactions between phospholipid antibodies and the protein C system. Blood Coagul Fibrinolysis 1994; 5: 37-41.
40. Larsson J, Olafdottir E, Bauer B. Activated protein C resistance in young adults with central retinal vein occlusion. Br J Ophthalmol 1996; 80: 200-2.
41. Beck RW, Servais GE, Hayreh SS. Anterior ischemic optic neuropathy: cup to disc ratio and its role in pathogenesis. Ophthalmology 1987; 94: 1503-8.
42. Lavin PJM. Optic disc risk factors for non-arteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1994; 117: 822.
43. McLeod D, Marshall J, Krohner EM. Role of axoplasmic transport in the pathophysiology of ischemic disc swelling. Br J Ophthalmol 1980; 64: 1488-502.
44. Beck RW, Savino PJ, Repka MX, Schatz NJ, Sergott RC. Optic disc structure in anterior ischemic optic neuropathy. Ophthalmology 1984; 91: 1334-7.
45. Hayreh SS. Axoplasmic transport and ischemic disc swelling. Br J. Ophthalmol 1981; 65: 70-71.
46. Watts MT, Greaves M, Clearkin LG, Malia RG, Cooper SM. An-tiphospholipid antibodies and ischemic optic neuropathy [letter]. Lancet 355(8793): 613-4, 1990.
47. Ogino S, Iwamoto K, Yamamoto H, Yamaguchi K, Kondo M. A case of optic neuritis associated with anticardiolipin antibodies rietter]. Rinsho Shikeigaku 1992; 32: 330-2.
48. Smith DB, Ens GE. Protein C deficiency: a cause of amaurosis fugax [letter]? J Neurol Neurosurg Psychiatry 1987; 50: 361-2.
49. Kleiner RC, Najarian LV, Schatten S, Jabs DA, Patz A, Kaplan HJ. Vaso-occlusive retinopathy associated with anliphospholipid antibodies (lupus anticoagulant retinopathy). Ophthalmology 1989; 96: 896-904.
50. Dhote R, Bachmeyer C, Horellou MH, Toulon CB. Central retinal vein thrombosis associated with resistance to activated protein C. Am J Ophthalmol 1995; 120: 388-9.
51. Williamson TH, Rumley A, Lowe GDO. Blood viscosity, coagulation, and activated protein C resistance in central retinal vain occlusion: a population controlled study. Br J. Ophthalmol 1996; 80: 203-8.
52. Hunt BJ. Activated protein C and retinal vein occlusion [letter]. Br J Ophthalmol 1996; 80: 194.